About Careers MedBlog Contact us

Cancer Drug may be Beneficial for People With Fragile X Syndrome

by Kathy Jones on November 28, 2014 at 5:30 PM
Font : A-A+

 Cancer Drug may be Beneficial for People With Fragile X Syndrome

Researchers at University of Edinburgh and McGill University have found that a drug that is currently being tested as a treatment for cancer is also effective in helping people suffering from a common inherited form of autism.

Fragile X Syndrome is the most common genetic cause of autism spectrum disorders. It affects around 1 in 4,000 boys and 1 in 6,000 girls. Currently, there is no cure.


The scientists, who have identified a chemical pathway that goes awry in the brains of Fragile X patients, say a cancer drug candidate could reverse their behavioural symptoms. The researchers have found that a naturally occurring anti-fungal called cercosporamide can block the pathway and improve sociability in mice with the condition.

The team identified a key molecule - eIF4E - that drives excess protein production in the brains of Fragile X patients. This can cause behavioural symptoms that include learning difficulties. It can also lead to more serious intellectual disabilities, delays in speech and language development and problems with social interactions.

"We found that eIF4E regulates the production of an enzyme called MMP-9, which breaks down and re-orders the connections between brain cells called synapses," says Nahum Sonenberg, McGill professor in the Faculty of Medicine and the Goodman Cancer Research Centre and co-author of the study, "Excess MMP-9 disrupts communication between brain cells, leading to changes in behaviour."

The team found that treatment with cercosporamide blocks the activity of eIF4E, and therefore reduces the amounts of MMP-9, and reverses the behavioural symptoms in mice with a version of Fragile X Syndrome. The new findings suggest that it could have a use as a treatment for patients with Fragile X Syndrome. The study is published in the journal Cell Reports.

Findings open door to targeted treatments

McGill post-doctoral student and a co-first author of the study Arkady Khoutorsky said that "the enzyme MMP-9 has been implicated before in Fragile X Syndrome. What''s new in our research is the demonstration that the symptoms of the disease can be controlled by manipulating eIF4E activity with available drug candidates."

"Our findings open the door to targeted treatments for Fragile X Syndrome," says Christos Gkogkas, of the University of Edinburgh''s Patrick Wild Centre for Research into Autism, Fragile X Syndrome and Intellectual Disabilities. "By designing treatments that block just this pathway, it is hoped that we can limit the potential side-effects and develop therapies that are more efficient than general treatment approaches."

The study was funded by a Canadian Institute of Health Research operating grant, the Azrieli Foundation and Brain Canada, the Fonds de la Recherche du Quebec-Santé.

Pharmacogenetic Inhibition of eIF4E-Dependent Mmp9 mRNA Translation Reverses Fragile X
Syndrome-like Phenotypes, by Christos G. Gkogkas, Arkady Khoutorsky, Jean-Claude Lacaille, Nahum Sonenberg will be published in Cell Reports on November 27, 2014

For further information, please contact:
Cynthia Lee
Media Relations Office, McGill University
Tel +1 514 398 6754

Jen Middleton, Press and PR Office, University of Edinburgh
Tel +44 131 650 6514
Email jen.middleton@ed.ac.uk

Source: Newswise

Recommended Reading

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

Cancer Drug may be Beneficial for People With Fragile X Syndrome Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests